<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00089947</url>
  </required_header>
  <id_info>
    <org_study_id>SMC-101-1025</org_study_id>
    <nct_id>NCT00089947</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effect of Thymoglobulin and Reduced Doses of Steroids to Prevent Renal Transplant Rejection</brief_title>
  <official_title>Randomized, Prospective, Phase 2 Study Comparing Thymoglobulin in a Rapid Discontinuation of Corticosteroids Protocol With Standard Corticosteroid Therapy in Living Donor Renal Transplantation Using Mycophenolate Mofetil and Tacrolimus Maintenance Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      This study involves the use of a drug called Thymoglobulin, which is approved in the US to&#xD;
      treat kidney transplant rejection and in Canada to treat and to prevent kidney transplant&#xD;
      rejection.&#xD;
&#xD;
      This study will evaluate the effect of Thymoglobulin and reduced doses of steroids to prevent&#xD;
      renal transplant rejection and will provide a basis for future evaluations of Thymoglobulin&#xD;
      as an immunosuppressive agent to help prevent renal transplant rejection.&#xD;
&#xD;
      Subjects meeting all inclusion and exclusion criteria are eligible to participate in this&#xD;
      study. In addition to standard treatment, study participants will receive either&#xD;
      Thymoglobulin with rapid discontinuation of steroids or steroids per hospital standards for&#xD;
      at least the first 90 days after transplant. The treatment assignment is random and is not&#xD;
      chosen by the subject or their physician.&#xD;
&#xD;
      Subjects will be monitored during treatment with Thymoglobulin and during the transplant&#xD;
      hospitalization. Additional subject monitoring occurs at Months 1, 3, 6 and 12 following the&#xD;
      transplant.&#xD;
&#xD;
      Approximately 150 study subjects from 15-20 transplant centers in the United States will be&#xD;
      enrolled.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">December 2005</completion_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>This study will evaluate the effect of Thymoglobulin and reduced doses of steroids to prevent renal transplant rejection, organ loss and death at 6 months.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate patient kidney function after transplantation and the overall safety of Thymoglobulin in this patient population.</measure>
  </secondary_outcome>
  <enrollment>150</enrollment>
  <condition>Renal Transplantation</condition>
  <condition>Graft Rejection</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult living donor renal transplant recipient&#xD;
&#xD;
          -  Age greater than or equal to 18&#xD;
&#xD;
          -  If female and of childbearing potential: a) must not be lactating; b) must have a&#xD;
             negative serum B-human chorionic gonadotropin (HCG) test within 24 hours prior to&#xD;
             Study Day 0 (Day of Transplant) and; c) must agree to practice an acceptable and&#xD;
             reliable form of contraception during the study; and&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Human Leukocyte Antibody (HLA) identical matched living donor transplant recipient&#xD;
&#xD;
          -  &gt; 2 previous transplants&#xD;
&#xD;
          -  Current panel reactive antibody (PRA) &gt; 20%&#xD;
&#xD;
          -  History of a positive cross-match with the donor&#xD;
&#xD;
          -  Active donor or recipient serology positive for human immunodeficiency virus (HIV),&#xD;
             Hepatitis B virus (HBV) or Hepatitis C virus (HCV)&#xD;
&#xD;
          -  Loss of first kidney transplant in &lt; 1 year&#xD;
&#xD;
          -  History of noncompliance in clinical trial(s)&#xD;
&#xD;
          -  History of chronic CS or immunosuppressive use except for inhaled CS to treat asthma&#xD;
&#xD;
          -  Use of any investigational products during the 90 days prior to screening&#xD;
&#xD;
          -  Requirement for multiple organ transplant&#xD;
&#xD;
          -  Patient without a functioning urinary bladder prior to transplant (e.g. patients with&#xD;
             self catheterization will be excluded)&#xD;
&#xD;
          -  Known contraindication to administration of rabbit antithymocyte globulin&#xD;
&#xD;
          -  Currently abusing drugs or alcohol&#xD;
&#xD;
          -  In the opinion of the investigator, at high risk for poor compliance&#xD;
&#xD;
          -  In the opinion of the investigator, has a significant medical or psychosocial problem&#xD;
             or unstable disease state that warrants exclusion from the study. Examples of&#xD;
             significant problems include, but are not limited to morbid obesity and severe cardiac&#xD;
             disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Genzyme, a Sanofi Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arkansas for Medical Science</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keck USC School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Diego Medical Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Pacific Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Health Sciences Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oschner Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Barnabas Medical Center</name>
      <address>
        <city>Livingston</city>
        <state>New Jersey</state>
        <zip>07039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Transplant Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Virginia</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.thymoglobulin.com/home/thymo_pdf_pi.pdf</url>
    <description>US FDA Approved Full Prescribing Information for Thymoglobulin®</description>
  </link>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>August 18, 2004</study_first_submitted>
  <study_first_submitted_qc>August 19, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2004</study_first_posted>
  <last_update_submitted>March 16, 2015</last_update_submitted>
  <last_update_submitted_qc>March 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2015</last_update_posted>
  <responsible_party>
    <name_title>Medical Monitor</name_title>
    <organization>Genzyme Corporation</organization>
  </responsible_party>
  <keyword>Anti-T cell antibodies</keyword>
  <keyword>Living Donor Renal Transplantation</keyword>
  <keyword>Acute Renal Allograft Rejection</keyword>
  <keyword>Induction Therapy with Reduction of Calcineurin inhibitors</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

